Arcus Biosciences Inc., a clinical-stage biopharmaceutical company, has announced new employment inducement grants for three new employees. The Compensation Committee of the company's Board of Directors has approved options for these employees to purchase a total of 19,300 shares of the company's common stock at an exercise price of $12.19 per share, based on the closing price as of September 8, 2025. Additionally, the employees have been granted restricted stock units to acquire a total of 9,700 shares of common stock. These equity awards are part of the company's initiative to support their growth and development in the field of cancer therapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908291539) on September 08, 2025, and is solely responsible for the information contained therein.